BioCryst Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 1995
Cash & Equivalents	112.45	306.24	507.73	274.35	115.72	28.28	53.57	23.65	30.51	54.69	Upgrade
Short-Term Investments	278.34	119.54	3.21	28.24	22.05	77.74	64.12	32.55	22.66	18.23	Upgrade
Cash & Cash Equivalents	390.79	425.78	510.95	302.59	137.78	106.01	117.68	56.2	53.18	72.92	Upgrade
Cash Growth	-8.22%	-16.67%	68.86%	119.62%	29.96%	-9.92%	109.42%	5.68%	-27.08%	90.87%	Upgrade
Receivables	56.95	50.6	29.41	8.65	22.15	4.29	6.12	8.77	6.24	9.49	Upgrade
Inventory	28.68	27.53	15.79	7.04	0	1.65	0	0.5	1.61	0.68	Upgrade
Other Current Assets	19.54	12.59	9.99	5.53	4.42	2.4	1.59	1.52	2.76	6.25	Upgrade
Total Current Assets	495.97	516.5	566.14	323.8	164.35	114.35	125.39	66.99	63.79	89.34	Upgrade
Property, Plant & Equipment	7.91	8.62	8.71	7.11	7.35	9.14	9.55	9.92	5.15	0.21	Upgrade
Long-Term Investments	0	18.08	6.83	0	0	22.38	41.3	8.93	47.68	41.12	Upgrade
Other Long-Term Assets	13.08	6.81	6.47	3.8	3.59	0.98	2.03	4.01	5.73	6.21	Upgrade
Total Long-Term Assets	20.99	33.5	22.02	10.92	10.94	32.49	52.87	22.86	58.57	47.53	Upgrade
Total Assets	516.96	550	588.15	334.72	175.28	146.84	178.26	89.85	122.36	136.87	Upgrade
Accounts Payable	20.89	14.36	27.81	18.71	13.99	7.77	6.34	4.27	9.31	2.85	Upgrade
Deferred Revenue	0	1.22	1.42	0.15	2.12	0.22	8.48	10.21	11.84	10.64	Upgrade
Current Debt	26.21	2.37	1.82	31.18	39.96	33.75	35.22	28.24	27.8	30	Upgrade
Other Current Liabilities	102.88	87.57	72.67	55.61	36.27	27.74	24.79	11.64	13.31	13.81	Upgrade
Total Current Liabilities	149.99	105.51	103.72	105.65	92.34	69.48	74.84	54.36	62.26	57.29	Upgrade
Long-Term Debt	822.5	739.08	591.42	248.32	44.7	28.08	19.5	25.48	2.38	0	Upgrade
Other Long-Term Liabilities	0	0	0	0	0	0.05	0.16	8.43	10	3.95	Upgrade
Total Long-Term Liabilities	822.5	739.08	591.42	248.32	44.7	28.13	19.66	33.91	12.38	3.95	Upgrade
Total Liabilities	972.49	844.6	695.14	353.98	137.03	97.61	94.49	88.27	74.64	61.24	Upgrade
Total Debt	848.71	741.45	593.24	279.5	84.65	61.82	54.72	53.72	30.18	30	Upgrade
Debt Growth	14.47%	24.98%	112.25%	230.17%	36.93%	12.98%	1.86%	78.02%	0.60%	-	Upgrade
Retained Earnings	-1,681.16	-1,454.62	-1,207.5	-1,023.44	-840.63	-731.97	-631.84	-566.06	-510.92	-467.9	Upgrade
Comprehensive Income	1.34	0.03	0.18	0	0.04	-0.3	-0.24	-0.01	-0.21	-0.13	Upgrade
Shareholders' Equity	-455.53	-294.6	-106.99	-19.26	38.25	49.24	83.77	1.58	47.72	75.64	Upgrade
Net Cash / Debt	-457.92	-315.67	-82.29	23.09	53.12	44.19	62.96	2.47	23	42.92	Upgrade
Net Cash / Debt Growth	-	-	-	-56.55%	20.22%	-29.82%	2446.97%	-89.25%	-46.42%	423.06%	Upgrade
Net Cash Per Share	-2.38	-1.70	-0.46	0.14	0.46	0.43	0.75	0.03	0.32	0.64	Upgrade
Working Capital	345.98	410.99	462.42	218.15	72.01	44.88	50.56	12.63	1.54	32.05	Upgrade
Book Value Per Share	-2.37	-1.58	-0.60	-0.12	0.33	0.48	0.99	0.02	0.66	1.13	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).